<DOC>
	<DOC>NCT01764633</DOC>
	<brief_summary>The primary hypothesis is that additional LDL-C lowering with Evolocumab (AMG 145) when used in addition to other treatment for dyslipidemia is well tolerated and decreases the risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization in subjects with clinically evident cardiovascular disease.</brief_summary>
	<brief_title>Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Male or female ≥ 40 to ≤ 85 years of age History of clinically evident cardiovascular disease at high risk for a recurrent event Fasting LDLC ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or nonHDLC ≥ 100 mg/dL (&gt; 2.6 mmol/L) Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) NYHA class III or IV, or last known left ventricular ejection fraction &lt; 30% Uncontrolled hypertension Uncontrolled or recurrent ventricular tachycardia Untreated hyperthyroidism or hypothyroidism Homozygous familial hypercholesterolemia LDL or plasma apheresis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Treatment for high cholesterol</keyword>
	<keyword>Lowering cholesterol</keyword>
	<keyword>Lowering high cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>